GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Windtree Therapeutics Inc (NAS:WINT) » Definitions » FCF Yield %

WINT (Windtree Therapeutics) FCF Yield % : -1,239.58 (As of Mar. 26, 2025)


View and export this data going back to 1984. Start your Free Trial

What is Windtree Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Windtree Therapeutics's Trailing 12-Month Free Cash Flow is $-15.28 Mil, and Market Cap is $1.23 Mil. Therefore, Windtree Therapeutics's FCF Yield % for today is -1,239.58%.

The historical rank and industry rank for Windtree Therapeutics's FCF Yield % or its related term are showing as below:

WINT' s FCF Yield % Range Over the Past 10 Years
Min: -1452905.41   Med: -5.48   Max: 9.16
Current: -1239.58


During the past 13 years, the highest FCF Yield % of Windtree Therapeutics was 9.16%. The lowest was -1452905.41%. And the median was -5.48%.

WINT's FCF Yield % is ranked worse than
98.47% of 1502 companies
in the Biotechnology industry
Industry Median: -14.32 vs WINT: -1239.58

Windtree Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.


Windtree Therapeutics FCF Yield % Historical Data

The historical data trend for Windtree Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windtree Therapeutics FCF Yield % Chart

Windtree Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -33.15 -254.44 -296.97

Windtree Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -300.95 -314.99 -369.99 -483.07 -458.93

Competitive Comparison of Windtree Therapeutics's FCF Yield %

For the Biotechnology subindustry, Windtree Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Windtree Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Windtree Therapeutics's FCF Yield % falls into.



Windtree Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Windtree Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-13.452 / 4.529700042
=-296.97%

Windtree Therapeutics's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-6.444 * 4 / 5.6165
=-458.93%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Windtree Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Windtree Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Windtree Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Windtree Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Executives
Craig Fraser director, officer: Chief Executive Officer AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Jamie Mcandrew officer: VP, Controller, & CAO WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Mark Strobeck director 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
John P. Hamill officer: SVP & CFO 4092 NEW HOPE ROAD, FURLONG PA 18925
Bioengine Capital Inc. 10 percent owner 7 F., NO. 3-2, PARK ST., NANGANG DIST., TAIPEI F5 11503
Center Laboratories, Inc. 10 percent owner 7 ., NO. 3-2, PARK ST. NANGANG DIST., TAIPEI F5 11503
Diane Carman officer: SVP & General Counsel 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Eric Curtis officer: SVP & COO ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Steven Simonson officer: SVP, Chief Development Officer 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Evan Loh director 75 KNEELAND STREET, BOSTON MA 02111
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Robert A Scott director
Joseph M Mahady director 16640 CHESTERFIELD GROVE RD, SUITE 200, CHESTERFIELD MO 63005
Brian D Schreiber director 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976